2025 · 3rd Quarter (July 1 - Sep 30)

ALNYLAM PHARMACEUTICALS, INC.

Filed by SPLITOAK STRATEGIES LLC.

Open official filing

Source-reported fields

Filing overview

Type: 3rd Quarter - Report
Posted: Oct 20, 2025
Income: $60,000.00
Expenses: Not reported
Registrant: SPLITOAK STRATEGIES LLC
Client: ALNYLAM PHARMACEUTICALS, INC.
Filing UUID: af6c6e3e-5bb7-416d-8026-7e1b7980c142
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; H.R. 946/S. 1862, ORPHAN Cures Act; P.L. 119-21

Literal federal measure citations: H.R. 1672, H.R. 946, S. 1862

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.